Dawn E. Smilek

The immune cell landscape in kidneys of patients with lupus nephritis

Arnon Arazi, Deepak A. Rao, Céline C. Berthier et al. · Nature Immunology · 2019 · 835 citations · Full text

Medicine, Immunology, Nephrology +14

Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy

David C. Wraith, Dawn E. Smilek, Dennis J. Mitchell et al. · Cell · 1989 · 391 citations

Life Sciences, Immunology, Neuroscience +16

Predictors of Long‐Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‐Lupus Nephritis Cohort

Maria Dall’Era, Miriam G. Cisternas, Dawn E. Smilek et al. · Arthritis & Rheumatology · 2015 · 318 citations

Medicine, Biostatistics, Nephrology +17

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis

Yemil Atisha‐Fregoso, Susan Malkiel, Kristina M. Harris et al. · Arthritis & Rheumatology · 2020 · 208 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.

Dawn E. Smilek, David C. Wraith, Suzanne Hodgkinson et al. · Proceedings of the National Academy of Sciences · 1991 · 165 citations

Life Sciences, Immunology, Neuroscience +17